After debunking earlier rumors that it was acquiring RAS superstar Revolution Medicines, AbbVie is now taking a more definitive step into the red-hot cancer field. The Chicago pharma has agreed to help finance a KRAS inhibitor from Kestrel Therapeutics in a deal that could hit up to $1.45 billion in value and end potentially with AbbVie buying the company outright. AbbVie has not taken part in the recent pharma M&A flurry, led by Eli Lilly and Gilead Sciences, but did ink a few deals several months ago.
Read the full article: AbbVie Dips into Boiling RAS Waters with $1.45B Biobucks Deal That Could End in Acquisition //
Source: https://www.fiercebiotech.com/biotech/abbvie-dips-boiling-ras-waters-145b-biobucks-deal-could-end-acquisition